Reuters exclusively reports Bangladesh firm to begin producing COVID-19 drug remdesivir

Reuters reported exclusively that one of Bangladesh’s largest drugmakers, Beximco Pharmaceuticals, will start production this month of the experimental antiviral drug remdesivir, which has shown promise in fighting the new coronavirus. The company plans to price the drug, which is given via intravenous infusion, at between 5,000 and 6,000 takas per vial ($59-$71/per vial), Beximco’s Chief Operating Officer Rabbur Reza told Reuters, adding a patient might need anywhere between 5 and 11 vials.